NCT04790214 (CARECA-CHF) is a NA clinical trial of CHF Patients in Chronic Heart Failure (CHF), sponsored by Yaounde Central Hospital.

Who is sponsoring NCT04790214?

NCT04790214 is sponsored by Yaounde Central Hospital.

What drugs are being tested in NCT04790214?

Interventions in NCT04790214: CHF Patients.

What condition does NCT04790214 study?

NCT04790214 studies Chronic Heart Failure (CHF).

Is NCT04790214 still recruiting?

NCT04790214 is currently status unknown. Last updated 10 March 2021.

Last reviewed 2021-03-10 · How we verify

NCT04790214: CARECA-CHF

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of a Cardiac Rehabilitation Program on Chronic Heart Failure Patients in Yaoundé, Cameroon

Status unknown NA Last updated 10 March 2021

What this trial tests

NA trial testing CHF Patients in Chronic Heart Failure (CHF) in 30 participants. Status unknown.

Timeline

1 March 2021

Primary endpoint
1 June 2021

1 September 2021

Quick facts

Lead sponsor	Yaounde Central Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	supportive care
Enrollment	30
Start date	1 March 2021
Primary completion	1 June 2021
Estimated completion	1 September 2021
Sites	1 location across Cameroon

Drugs / interventions tested

CHF Patients

Conditions studied

Chronic Heart Failure (CHF) — all drugs for Chronic Heart Failure (CHF) →

Sponsor

Yaounde Central Hospital

Who can join

Adults 21 to 80, any sex, with Chronic Heart Failure (CHF). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

CARECA-CHF study is a non-randomized, prospective, single-arm study, enrolled ambulatory patients with stable chronic heart failure \[New York Heart Association (NYHA) class II/III\]. Patients will be followed-up during a period of 06-08 weeks. The aim of this study is to assess the effect of a cardiac rehabilitation program on patients with stable chronic heart failure in Yaoundé, Cameroon.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Yaounde Central Hospital trials

Trials by the same sponsor.

NCT04715295 — Safety and Efficacy of Doxycycline and Rivaroxaban in COVID-19 · Phase 4 · unknown
NCT05013346 — Characteristics of Young-onset Diabetes in Sub-Saharan Africa (YODA) Study · unknown
NCT04255992 — Short Term Cardiovascular Effects and Oxidative Status of Calcium and Vitamin D Supplementation of Postmenopausal Hypert · Phase 4 · completed
NCT04254042 — Comparative Effects of Perindopril and Zofenopril on Blood Pressure Control and Oxidative Status Blacks Hypertensive Pat · Phase 4 · completed
NCT03909945 — Evaluation of an Antihypertensive Food Supplement Based on Aqueous Extract From Annona Muricata Sheets · Phase 2, PHASE3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04790214 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yaounde Central Hospital
Last refreshed: 10 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04790214.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing